NEW YORK, NY / ACCESSWIRE / May 25, 2016 / Bronstein, Gewirtz & Grossman, LLC, reminds investors of class action against Brixmor Property Group, Inc. (“Brixmor” or the “Company”) (NYSE: BRX). The class action has been filed on behalf of a class consisting of all persons or entities who purchased Brixmor securities during the period between October 27, 2014 and February 5, 2016 inclusive (the “Class Period”).

This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).

Brixmor owns and operates one of the nation’s largest wholly owned portfolio of grocery-anchored community and neighborhood shopping centers, with more than 520 properties strategically located across 38 states.

The Complaint alleges that throughout the Class Period, Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) Brixmor and its senior executives purposefully distorted Brixmor’s financial results by biasing income items for nine quarters to attain consistent quarterly growths; (2) Brixmor lacked sufficient internal and financial controls; and (3) as a result, Brixmor’s public statements were materially false and misleading at all relevant times. Once true details entered the market, investors suffered damages.

A class action lawsuit has already been filed. If you wish to review a copy of the Complaint and join the action, visit the firm’s website: http://www.bgandg.com/#!brx/hu6wo. To discuss this action, or have any questions, please contact Peretz Bronstein, Esq. or Eitan Kimelman, Investor Relations Coordinator of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in Brixmor you have until May 31,
2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

ReleaseID: 439569

VANCOUVER, BC / ACCESSWIRE / May 25, 2016 / Golden Predator Mining Corp. (TSX.V: GPY) (the “Company) is pleased to announce the completion of its previously announced private placement. The private placement was fully subscribed, resulting in gross proceeds to the Company of $4,320,000 from the sale of 27,000,000 units (the “Units“) at a price of $0.16 per Unit. Each Unit consists of one common share (the “Shares“) and one share purchase warrant (the “Warrants“). Each Warrant entitles the holder to purchase one additional Share at a price of $0.21 for a period of two years from the date of issue of the Warrants. $904,000 worth of Units are comprised of flow-through shares and non-flow-through warrants, and $3,416,000 worth of Units are comprised of non-flow-through shares and non-flow-through warrants.

As a result of the closing of the financing:

• William M. Sheriff acquired 1.9 million units, and now holds a total of 11.654 million common shares representing 17.48 per cent of the issued and outstanding common shares of the Company. In addition Mr. Sheriff holds 1.9 million warrants, 275,000 stock options, and an option to acquire from Till Capital Ltd. up to 10,312,154 million shares of the Company, which if exercised would increase his percentage ownership to 35.07%;
• Pat DiCapo owns 3.5 million common shares and 4 million warrants, representing 5.25 per cent of the issued and outstanding common shares of the issuer, or 10.61 per cent upon exercise of the warrants. In addition, PowerOne Capital Markets Limited, a joint actor of Mr. DiCapo, acquired ownership and control of 1,274,000 Broker Warrants, each Broker Warrant entitling the Finder to acquire one Broker Unit, representing approximately 3.68% of the Common Shares on a partially diluted basis, assuming exercise of the Broker Warrants and Broker Unit Warrants only, and when taken together with the Common Shares acquired by Mr. DiCapo, representing approximately 8.93% of the current issued and outstanding Common Shares (or approximately 13.72% on a partially diluted basis, assuming exercise of the Warrants, Broker Warrants and Broker Unit Warrants only);
• FCMI Parent Co., an entity controlled by Albert D. Friedberg and members of his immediate family, owns 4 million common shares and 4 million warrants of the issuer comprising 6 per cent of the issued and outstanding common shares of the issuer or 11.32 per cent upon exercise of the warrants;
• McEwen Mining Inc., a publicly traded company listed on the NYSE and TSX, owns 3.125 million common shares and 3.125 million warrants, representing 4.69 per cent of the issued and outstanding common shares of the issuer, or 8.95 per cent upon exercise of the warrants.

The above percentages are calculated based on 66,671,215 shares issued and outstanding and in the case of diluted holdings assumes the exercise of all of the warrants and options beneficially owned by the offeror, and that no other securities, including those convertible into, or exercisable for, the issuer’s securities, are issued, converted or exercised. Prior to the financing, the FCMI Parent Co. and McEwen Mining Inc. did not own any securities of the issuer.

The Units acquired by the purchasers referred to above were acquired for investment purposes, and each of the purchasers or one or more of their affiliates may, depending on market and other conditions, increase or decrease its beneficial ownership of common shares or other securities of the issuer whether in the open market, by privately negotiated agreement or otherwise.

PowerOne Capital Markets Limited acted as a finder in connection with a portion of the Canadian participants in the private placement. An aggregate of 1,274,000 broker warrants (“Broker Warrants“) were issued to the finder, each Broker Warrant entitling the finder to purchase a broker unit of the company (“Broker Unit“) at a price of $0.16 per Broker Unit for a period of two years from the date of closing of the private placement. Each Broker Unit is comprised of one common share and one broker unit warrant (“Broker Unit Warrant“). Each Broker Unit Warrant entitles the Finder to purchase one common share at an exercise price of $0.21 per common share for a period of two years from the date of closing of the private placement.

All securities issued will be subject to a four-month hold period.

Proceeds from the financing will be applied to the Company’s 3 Aces project and Brewery Creek project and general working capital.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities. The securities referenced in this news release have not and will not be registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

Golden Predator Mining Corp.

Golden Predator Mining Corp., a Canadian gold mineral exploration company, is focused on advancing the 3 Aces Project and Brewery Creek project in Canada’s North. The Company has undertaken a bulk sampling at the 3 Aces project, focused on high grade native gold bearing quartz veins, to define the distribution and grade of gold in the veins. The Company’s Brewery Creek Project is a past producing heap leach gold mine with a Preliminary Economic Assessment, next steps include advancing the project through feasibility and permitting.

For additional information:

Janet Lee-Sheriff
Chief Executive Officer
(214) 304-9552
info@goldenpredator.com
www.goldenpredator.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein. This press release contains forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations that the private placement will complete as described herein, that the Project will advance through permitting and feasibility. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.

SOURCE: Golden Predator Mining Corp.

ReleaseID: 440389

HONG KONG, CHINA / ACCESSWIRE / May 25, 2016 / Recently, the bio-engineered cornea “Acornea” of China Regenerative Medicine International Limited (CRMI) was listed as one of the five key science projects in the special report “China’s Science Revolution” of BBC.

Inside a cavernous, brightly lit shed, row upon row of pigs snuffle and shuffle around in their pens. Pork is big business in China, and this farm in the Guangdong Province in the south of the country has 2,000 pigs.

These animals are bred for their meat – but there’s now a new use for the pig parts that aren’t destined for the dinner table.

Once the pigs are killed, their corneas – the thin, transparent films that cover the front of the eye – are removed from some of them and set aside, to be transplanted into humans.

A few hours’ drive away is China’s oldest, and largest, eye hospital – the Zhongshan Ophthalmic Centre. China accounts for a fifth of the world’s blind people: about eight million of its 1.4-billion population.

As Dr Yuan Jin walks around the busy ward, he tells me that corneal disease is responsible for between 3.5 and five million of these cases.

Injury or infection of the cornea, if untreated, can eventually lead to loss of sight – and for many, the only hope is a transplant. But the waiting list is extremely long.

Once the main source of organs in China was from executed prisoners. But last year, the government stopped this controversial practice, and instead began encouraging people to sign up to donate their corneas after death.

Few, though, are choosing to do so. Yuan explains:

“In China, people have traditional opinions. They don’t like to give their corneas. This is the main reason why we can carry out just 5,000 cornea transplants a year.”

But today he is examining the eyes of patients who have been given pigs’ corneas.

The Chinese government gave the go-ahead for this experimental procedure last year, and about 200 operations have now been carried out.

Fifty-eight-year-old Wu Pinggui is one of the latest recipients.

One of his corneas became infected after an insect flew into his eye. “I didn’t take care of the injury and it got worse,” he tells me. “My eyes became red, swollen and painful.”

Eventually he lost his sight in that eye – and subsequently lost his job as a security guard. Now, 24 hours after surgery, some sight is returning.

I ask him if he was surprised to be offered an animal’s cornea. “I wasn’t too surprised, I trusted the doctor’s decision,” he says.

Just 35 years ago, the city of Shenzhen was a fishing village. Today it’s been transformed into a hub for innovation, and China Regenerative Medicine International (CRMI), the company that has developed the new cornea procedure, has its laboratory here.

“We tried many animals – goats, dogs, pigs and cows,” says Dr Shao Zhengkang, the company’s chief executive, explaining that it took 10 years of research.

“Finally we found the structure of porcine corneas is very similar to a human’s.”

Inside the lab there are flasks filled with corneas that have been removed from the pigs. They are milky white and glutinous – and need to undergo a process called decellularisation.

Essentially the pig cells are stripped away, removing the animal DNA, proteins and lipids.

Anything that could cause the patient’s body to reject the tissue has to go. All viruses and bacteria are also inactivated, to prevent any diseases crossing from the animals into humans.

Just the basic shape, the collagen scaffolding, of the cornea is left behind.

Once transplanted, it is then repopulated with the patient’s human cells.

Shao shows me the final product. The cornea looks like a contact lens.

CRMI has spent 1bn Chinese Yuen (£100m, or $150m) developing it, but Shao admits the treatment is still at an early stage.

“It’s very different from the traditional treatment. It’s totally new. So it takes time to introduce to hospitals, patients and society,” he says.

The company says the success rate for the operations is above 90% – about the same rate achieved with human transplants. But some believe that China is moving too quickly, without assessing the risks – or the ethics.

Animal-to-human-transplantation is just one area where China is straying on to controversial ground. Work on stem cells, cloning and gene-editing of embryos is also making waves in the international scientific community.

“I think some people have the view that China is at a frontier in science, and therefore there’s a lot of ambition and appetite to explore the latest technology,” says Charlotte Lui from Springer Nature.

“And therefore, in that context, the time and the effort required to debate, to discuss and fully understand the consequences before embarking on something is probably not entirely there.”

But she says increasing scrutiny from other researchers around the world does seem to be changing this.

“Science is still relatively young in China,” she argues. “And the culture of doing science and ethics needs time to develop and cultivate.”

In the hospital, Wu Pinggui’s check-up has gone well. His eye is still a little red, but the healing process has begun.

He says this will make a big difference to his life – and he hopes that when he’s better, he’ll be able to find a new job.

The article is originally selected and transferred from BBC News
http://www.bbc.co.uk/news/resources/idt-0192822d-14f1-432b-bd25-92eab6466362

Document: http://n.eqs.com/c/fncls.ssp?u=WJTCLOUUKC
Document title: China’s Science Revolution-CRMI ‘Acornea’

25/05/2016 Dissemination of a Press Release, transmitted by EQS TodayIR – a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
Media archive at www.todayir.com.

SOURCE: China Regenerative Medicine International Ltd

ReleaseID: 440384

More Than 16 Million Americans Attempt To Quit Smoking Each Year without the Use of Drugs or Therapies–And Only 2-5% Successfully Quit In A Given Year; 22nd Century Group (NYSE MKT: XXII) Is Developing the Most Effective Solution to Date for These “Marooned” Consumers

WINDSOR, ON / ACCESSWIRE / May 25, 2016 / The Wealthy Biotech Trader (or “WBT”), an investment newsletter focused on showing everyday investors new opportunities in rapidly growing, little-known biotech, pharmaceutical and medical device stocks releasing impressive news and making market moves, would like to highlight the massive paradigm shift in the word of smoking cessation (quitting).

After being shunned by investors for the past couple of years, the tobacco sector has been slowly proving that it’s set for a meteoric rise and investors should pay more attention to it. Previous headwinds which had plagued the sector such as a declining smoking population and increased regulation have now fully played out, leaving a couple of stocks dealing a tobacco recipe that is ripe for investors’ picking.

22nd Century Group (NYSE MKT: XXII) is a plant biotechnology company whose 200 patents worth of technology allows it to decrease or increase the level of nicotine in tobacco plants through plant breeding and genetic engineering. The Company’s main focus, although counter intuitive as a cigarette marketer, is to reduce harm from smoking when compared to traditional big brands such as Marlboro (NYSE: PM).

Currently, the company’s products include high nicotine cigarettes marketed under the RED SUN brand name, very low nicotine cigarettes marketed under the MAGIC brand name and SPECTRUM research cigarettes with varying levels of nicotine for the U.S. government and accredited research organizations around the world–the company actually sells cigarettes to the National Institute of Health (NIH) for studies proving how low nicotine tobacco is the most effective way to reduce smoking rates and addictiveness of cigarettes. The U.S. Food and Drug Association (FDA) funded a landmark study that showed 22nd Century’s proprietary Very Low Nicotine cigarettes were “associated with reductions in smoking, nicotine exposure, and nicotine dependence, with minimal evidence of nicotine withdrawal, compensatory smoking, or serious adverse events.” See study here: http://www.nejm.org/doi/full/10.1056/NEJMsa1502403.

22nd Century is also in the process of developing a Very Low Nicotine cigarette as a novel and remarkably effective prescription smoking cessation aid–yes a prescription cigarette. Code named “X-22” the product reportedly causes no new side effects and yet seems to demonstrate higher efficacy rates than Pfizer’s (NYSE: PFE) market-leading, side effect-laden Chantix drug (which logs in excess of $600 million in sales each year). Pfizer must think XXII is on to something with this approach as they actually funded a study on smoking cessation where patients were treated with Chantix in combination with 22nd Century’s ultralow nicotine cigarettes, also with remarkable results.

With a US smoking cessation market size in excess of $1 Billion, and another $3 billion outside the States, one of the other mega-player in the smoking cessation space is the $100 Billion British Behemoth, GlaxoSmithKline Plc (NYSE: GSK). GSK is the maker of the prescription quit smoking pill Zyban which strangely is also used to treat depression and is also rife with extreme side effects. There is no doubt a need for a simpler, safer more effective solution and, with XXII recently announcing the active search for a strategic pharma partner for a phase III FDA study, commercialization of a blockbuster new product could be just around the corner pending approval.

In the ground-breaking 2015 clinical study funded by the FDA, independent researchers found that smokers who used 22nd Century’s (NYSE MKT: XXII) patented very low nicotine cigarettes (which contain approximately 95 percent less nicotine than ordinary cigarettes), smoked far fewer cigarettes per day, had minimal withdrawal symptoms and doubled their attempts to quit. This study was published in the highly-respected New England Journal of Medicine. And, currently, the FDA is funding an additional $20+ million smoking cessation study using the company’s very low nicotine cigarettes. Results of this study are only months away… and when this study is published, investors can expect the 22nd Century’s share price to move dramatically.

22nd Century Group has quite a bit going for it beyond tobacco as well. The company owns the exclusive patent rights in the U.S. which allow it to increase or decrease concentrations of the most important cannabinoids (the active ingredients) in cannabis. With this technology, 22nd Century is developing low-THC, high-CBD strains for the rapidly growing medical marijuana markets. With federal marijuana legalization nearing reality, the company is poised to capitalize on its impressive cannabis patent portfolio and growing cannabis technology.

With current share prices under $1, XXII is ripe for the picking based on a couple of other drivers as well. Having focused for years purely on research and development, the company is now turning its focus to monetizing its extensive patent portfolio. 2014 revenues were only $530,000 but, under a new CEO, 22nd Century earned more than $8.5 million in 2015. Furthermore, the Company just released Q1 2016 financials with the main highlight being a 400% revenue jump compared to the same quarter in 2015.

Not including licensing deals or international sales, publicly disclosed projections call for at least $12 million this year. Though not yet profitable, 22nd Century’s commercial expansion in Europe, Southeast Asia, and elsewhere should add significantly to the company’s bottom line in 2016, and with the FDA set to approve the world’s first ever Modified Risk Tobacco Products application for 22nd Century’s patented very low nicotine cigarettes (Brand A) before the end of this year, investors are looking at massive growth potential–these are similar to the Company’s X-22 smoking cessation aid, but may, upon clearance be marketed to retail customers as a “safer” or “reduced risk” cigarette. There are so many catalysts and binary moves this company can make over the next 6-12 months, it is difficult to believe this NYSE micro-cap still trades under $1. Undoubtedly, 22nd Century will not remain “under the radar” for much longer.

The Wealthy Biotech Trader is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook as well as newswire.

GET BREAKING NEWS FROM US:

To receive text Message alerts when new articles are released click here: http://clk2.it/k7oF5z.

Follow us on Twitter: @Wealthy_VC
Like us on Facebook: www.facebook.com/WealthyVC
Email: Info@WealthyVentureCapitalist.com

This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Biotech Trader and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Biotech Trader’s parent company has been compensated fifteen thousand dollars per month for a 12 month contract by 22nd Century Group. The Wealthy Biotech Trader encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Biotech Trader makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at www.wealthyventurecapitalist.com in order to view our entire disclaimer which covers most of the risks, biases and liability releases to have a full understanding after reading this article.

SOURCE: The Wealthy Biotech Trader

ReleaseID: 440387

• Q1 Revenue Increases 60.8% YoY to $860,240
• Q1 Gross Profit jumps166.3% YoY to $305,152

KUALA LUMPUR, MALAYSIA / ACCESSWIRE / May 25, 2016 / Vitaxel Group Limited (OTCQB: VXEL) (the “Company” or “Vitaxel”), on May 16, 2016 announced its financial results for the first quarter ended March 31, 2016.

First Quarter Highlights:

• Total revenues grew 60% to $860,240 for the first quarter of 2016 from $534,917 for the same period of last year
• Gross profit was $305,152, an increase of 166.3% compared to the same period of last year
• Growth margin increased significantly to 35.5% in the first quarter of 2016 from 21.4%in the same period of 2015
• Net Income grew 18.3% to $2,968 for the first quarter of 2016 from $2,509 for the same period of 2015

“We are very pleased to achieve excellent growth in revenue during the first quarter. We believe this is a strong indicator of the successful launched new program, which has been widely well-received in South East Asia. To keep the momentum and unlock the sales potential in the market worldwide, Vitaxel will continue the effort to expand its branches to other regions of Asia, such as China and Taiwan after a great success in opening the branches in Singapore and Thailand” Ryan Leong, CEO of Vitaxel commented.

“Currently we are promoting our product through seminars and road shows throughout our developed markets. We believe by educating our members with benefits of our products will further enhance our market exposure. Our product Amalaki is made from the Amla fruit, also known as the indian gooseberry. It is a great support and nutrition for the digestive tract, among other wonderful benefits including optimal function of the inner and outer skin, arteries, blood purification and liver rejuvenation hence promoting vitality and youth.

In the months to come we are also focusing on strengthening our presence in our newly developed market such as Thailand. By setting up Vitaxel Corp Thailand, an entity with direct selling licence, we believe the market has great potential for promoting our product and increasing our subsidiary Vitaxel Sdn Bhd’s revenue in the second half of the year.” according to Ryan Leong, CEO of Vitaxel.

Vitaxel Sdn Bhd is venturing into the China market by registering a company and setting up an office branch in Dongguan, Shenzhen. They intend to develop and launch a new program suited and compliant to the China market’s regulatory demands. The China Market is one of Vitaxel Group Limited’s main focus due to its large population and high density.

On the other hand, Vitaxel Online Mall has recently opened its services to the public. With the high competitiveness in the ecommerce marketplace, Vionmall differs itself from the crowded market by focusing in promoting entrepreneurship. In line with the trend today, Vionmall is expected to be popular marketplace platform for members and non-members alike. With the main focus on educating and helping small business to venture into ecommerce marketplace. Vitaxel Online Mall is fully committed in achieving stable users growth by fourth quarter of the year.

About Vitaxel Group Limited

Vitaxel Group Limited has three significant operating subsidiaries, Vitaxel SDN BHD (Vitaxel) and Vitaxel Online Mall SDN BHD (Vionmall), and the Vitaxel Singapore PTE. Ltd. (“Vitaxel Singapore”). Vitaxel is engaged in the direct selling industry utilizing a multilevel marketing model with an emphasis on travel, entertainment and lifestyle products and services. Vionmall is engaged in the development of online shopping platforms geared to Vitaxel and its members and third party providers of products and services.

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,” “expects” or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including the risk factors discussed in the Company’s periodic and other reports that are filed with the Securities and Exchange Commission and available on the SEC’s website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Contacts:

Email: info@vitaxel.com
Phone: 03-2143 2889

– Tables Below –

SOURCE: Vitaxel Group Limited

ReleaseID: 440386

Debt Relief Company Receives Record Number of 5 Star Reviews From Individuals and Businesses

HOLLYWOOD, FL / ACCESSWIRE / May 25, 2016 / CuraDebt, the company that helps provide thousands of individuals and small businesses with debt relief, announced today that they have surpassed 750 reviews from their satisfied clients. The CuraDebt reviews came from client testimonials on esteemed advocacy websites Customer Lobby and ShopperApproved.

CuraDebt is a 5-Star Excellence Award Winner from ShopperApproved and has received numerous industry accolades. In addition to the recent achievement, CuraDebt has been rated number one among debt settlement companies and tax debt relief companies by the consumer watchdog site, Top Consumer Reviews for seven years in a row. The US Tax Center at IRS.com, also endorsed CuraDebt as the #1 tax debt relief company to work with. The company credits their awards and honors to their ongoing commitment to transparency, integrity and superior service.

“This prestigious honor is a testament to our outstanding customer service and our tireless dedication to providing debt relief to thousands of Americans,” said Eric Michael Pemper, President of Curadebt. “When people experience financial difficulties in their lives we try to provide hope for them so they can resolve their debts and have a brighter future.”

CuraDebt’s trusted advisors help clients with debt negotiation, debt settlement, debt consolidation, debt management, credit counseling and tax debt relief. Their skilled professionals are experienced and knowledgeable about each of these services and review the best options for their clients. For tax debt reduction, CuraDebt has a group of experts in taxes, Tax Lawyers, Certified Public Accountants with over 25 years of experience and former IRS Officers, who work on their client’s behalf to solve their tax problems.

For more information about the company and its services, visit their website at http://www.curadebt.com.

About Curadebt:

For over 15 years, Curadebt has been helping people and small businesses resolve their financial difficulties. They have successfully advised over 10,000 individuals and families each year, and have settled over $100 million in consumer and business debt. CuraDebt specializes in providing expert help to resolve unsecured debts and tax issues.

Media Contact:

Jonathan Kirby
(877) 850-3328
marketing@curadebt.com
http://www.curadebt.com

SOURCE: Curadebt

ReleaseID: 440376